

Author's Accepted Manuscript

Outcomes of prostate cancer screening by 5-alpha reductase inhibitor usage

Teemu J. Murtola , Anniina Virkku , Kirsi Talala , Ulf-Håkan Stenman , Kimmo Taari , Teuvo L.J. Tammela , Anssi Auvinen



PII: S0022-5347(17)30290-2
DOI: [10.1016/j.juro.2017.02.069](https://doi.org/10.1016/j.juro.2017.02.069)
Reference: JURO 14388

To appear in: *The Journal of Urology*
Accepted Date: 9 February 2017

Please cite this article as: Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TL, Auvinen A, Outcomes of prostate cancer screening by 5-alpha reductase inhibitor usage, *The Journal of Urology*® (2017), doi: 10.1016/j.juro.2017.02.069.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

Outcomes of prostate cancer screening by 5-alpha reductase inhibitor usage

Teemu J. Murtola*, Anniina Virkku, Kirsi Talala, Ulf-Håkan Stenman, Kimmo Taari, Teuvo LJ Tammela, Anssi Auvinen

From the University of Tampere, School of Medicine, Tampere, Finland (TJM, AV, TLJT), Tampere University Hospital, Department of Urology, Tampere, Finland (TJM, TLJT), Finnish Cancer Registry, Helsinki, Finland (KTalala), University of Helsinki and Helsinki University Hospital, Department of Clinical Chemistry, Helsinki, Finland (UHS), University of Helsinki and Helsinki University Hospital, Department of Urology, Helsinki, Finland (KTaari) and University of Tampere, School of Health Sciences, Tampere, Finland (AA)

Running head: Prostate cancer screening in 5-ARI users

Keywords: Mass screening; Prostatic neoplasms; 5-alpha reductase inhibitors

*Correspondence to: Dr. Teemu J. Murtola, Tampere University Hospital, Department of Urology, Teiskontie 35, M-building, 3rd floor, PL 2000, 33521 Tampere. E-mail: teemu.murtola@uta.fi.
Phone: +358 3 311 65015

Download English Version:

<https://daneshyari.com/en/article/5686925>

Download Persian Version:

<https://daneshyari.com/article/5686925>

[Daneshyari.com](https://daneshyari.com)